Drug Trial Radar · NCT00642941
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
Last checked: Nov 20, 2026Latest source record: Feb 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
317
Actual
Start
Dec 18, 2007
Primary completion
Feb 19, 2014
Study completion Feb 19, 2014
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Sarcoma Alliance for Research through Collaboration
- First posted
- Mar 25, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study was primarily designed to determine objective response, progression-free survival (PFS), and the safety and tolerability of R1507 in participants with recurrent or refractory Ewing's sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma and other sarcomas including alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma, and myxoid liposarcoma.
Conditions
- Sarcoma
Interventions
RG1507Drug
Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Complete or Partial Response, According to World Health Organization (WHO) Criteria in Cohorts 2 to 8Time frame: Baseline up to 6 years (assessed at baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression)
- Progression-Free Survival (PFS) Rate According to WHO Response Criteria at 18 Weeks From Start of R2607 Treatment in Cohort 1Time frame: Baseline up to 18 weeks (assessed at baseline, every 6 weeks until disease progression)
- Percentage of Participants With Adverse Events (AEs) in Cohort 1 and 2Time frame: Baseline up to 6 years
Locations
41 sites in 11 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
UCLA School Of Medicine Mattel's Children's Hospital At UCLA; Division Of Hematology-Oncology
Los Angeles, California
Sarcoma Oncology Center
Santa Monica, California
Stanford Comprehensive Cancer Center
Stanford, California
Washington Cancer Institute; Washington Hospital Center
Washington D.C., District of Columbia
Kootenai Medical Center
Coeur d'Alene, Idaho
Johns Hopkins Hospital
Baltimore, Maryland
NIH/NCI
Bethesda, Maryland
Massachusetts General Hospital; Dana Farber Partnes Cancer Center
Boston, Massachusetts
Dana Farber Partners Can Ctr
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Nebraska Methodist Hospital; Onc Hem West
Omaha, Nebraska
Memorial Sloan Kettering Cancer Center
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Albert Einstein College of Medical Pediatrics; Department of Pediatrics
The Bronx, New York
Carolinas Hematology Oncology Associates; Investigational Drug Services - Pharmacy
Charlotte, North Carolina
Oregon Health and Science University Cancer Institute
Portland, Oregon
Pennsylvania Oncology Hema Asc
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Texas Children's Cancer Center; Baylor College of Medicine
Houston, Texas
University of Texas M.D. Anderson Cancer Center
Houston, Texas
Huntsman Cancer Institute; Orthopedic Center
Salt Lake City, Utah
Peter Maccallum Cancer Institute; Medical Oncology
Melbourne, Victoria, Australia
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, Canada
Institut Bergonie; Oncologie
Bordeaux, France
Centre Oscar Lambret; Chir Cancerologie General
Lille, France
Centre Leon Berard; Departement Oncologie Medicale
Lyon, France
Institut Curie; Oncologie Medicale
Paris, France
Institut Gustave Roussy; Service Pediatrique
Villejuif, France
HELIOS Klinikum Bad Saarow; Klinik für Innere Medizin III
Bad Saarow, Germany
Uniklinik Mannheim; Sektion Chirurgische Onkologie & Thoraxchirurgie
Mannheim, Germany
University Hospital Tübingen
Tübingen, Germany
Istituti Ortopedici Rizzoli
Bologna, Emilia-Romagna, Italy
Istituto Nazionale Tumori, Sarcoma Unit
Milan, Lombardy, Italy
Erasmus Mc - Daniel Den Hoed Kliniek; Medical Oncology
Rotterdam, Netherlands
Norwegian Radium Hospital
Oslo, Norway
Hospital Sant Joan De Deu
Esplugues de Llobregas, Barcelona, Spain
Skånes University Hospital, Skånes Department of Onclology
Lund, Sweden
UCL Hospital NHS Trust
London, United Kingdom
Royal Marsden Hospital; Dept of Med-Onc
London, United Kingdom
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.